Skip to main content

Table 2 Univariate and multivariable analysis of prognostic indicators on overall survival and cancer-specific survival for 1095 colorectal cancer patients

From: Different clinicopathologic features and favorable outcomes of patients with stage III left-sided colon cancer

Parameters

Overall survival

Cancer-specific survival

 

Univariate analysis

Multivariable analysis

Univariate analysis

Multivariable analysis

HRd (95 % CIe)

P value

HRd (95 % CIe)

P value

HRd (95 % CIe)

P value

HRd (95 % CIe)

P value

Age (years)

1.352 (1.099 – 1.664)

0.002*

1.347 (1.008 – 1.801)

0.044*

1.349 (1.096 – 1.601)

0.005*

1.362 (1.018 – 1.822)

0.037*

≥65 vs <65 (576/519)

Gender

1.098 (0.893 – 1.349)

0.377

1.036 (0.795 – 1.506)

0.792

1.096 (0.891 – 1.347)

0.386

1.032 (0.792 – 1.345)

0.817

Male vs Female (619/476)

Location

1.309 (1.041 – 1.647)

0.021*

1.172 (0.870 – 1.580)

0.296

1.303 (1.036 – 1.639)

0.024*

1.168 (0.867 – 1.572)

0.308

Right vs Left (249/846)

Tumor size

1.477 (1.200 – 1.817)

<0.001*

0.981 (0.745 – 1.292)

0.893

1.480 (1.203 – 1.821)

<0.001*

0.979 (0.744 – 1.289)

0.880

≥5 cm vs <5 cm (466/612)

Tumor depth

2.959 (2.088 – 4.193)

<0.001*

1.385 (0.596 – 3.220)

0.449

2.867 (2.094 – 4.205)

<0.001*

1.379 (0.593 – 3.205)

0.455

T3 + T4 vs T1 + T2 (853/235)

Lymph Node metastasis

2.464 (1.996 – 3.042)

<0.001*

1.055 (0.644 – 1.730)

0.831

2.460 (1.992 – 3.037)

<0.001*

1.060 (0.647 – 1.738)

0.816

Yes vs No (452/633)

AJCCa stage

3.441 (2.753 – 4.302)

<0.001*

1.375 (1.032 – 1.760)

0.015*

3.436 (2.748 – 4.295)

<0.001*

2.022 (1.065-2.099)

<0.001*

III + IV vs I + II (516/579)

Histology

1.997 (1.510 – 2.642)

<0.001*

1.655 (1.153 – 2.275)

0.006*

2.012 (1.521 – 2.662)

<0.001*

1.687 (1.177 – 2.419)

0.004*

PD vs MD + WDb (108/952)

Vascular invasion

2.796 (2.261 – 3.457)

<0.001*

1.642 (1.228 – 2.149)

0.001*

2.783 (2.251 – 3.441)

<0.001*

1.623 (1.226 – 2.418)

0.001*

Yes vs No (338/724)

Perineurial invasion

2.437 (1.971 – 3.013)

<0.001*

1.787 (1.358 – 2.351)

<0.001*

2.423 (1.960 – 2.996)

<0.001*

1.765 (1.341 – 2.322)

<0.001*

Yes vs No (391/673)

Pre-op CEAc (ng/ml)

3.047 (2.423 – 3.832)

<0.001*

1.249 (0.902 – 1.729)

0.180

3.053 (2.428 -–3.840)

<0.001*

1.245 (0.899 – 1.723)

0.186

≥5/ vs <5 (475/545)

Post-op CEA c (ng/ml)

5.567 (4.456 – 6.956)

<0.001*

2.492 (1.817 – 3.418)

<0.001*

5.591 (4.474 – 6.986)

<0.001*

2.514 (1.832 – 3.449)

<0.001*

≥5 vs <5 (266/752)

Pre-op albumin (g/dl)

1.847 (1.474 – 2.314)

<0.001*

1.245 (0.933 – 1.662)

0.137

1.828 (1.460 – 2.290)

<0.001*

1.221 (0.915 – 1.630)

0.175

<3.5 vs ≥3.5 (324/572)

Diabetes mellitus

1.012 (0.795 – 1.288)

0.923

0.962 (0.710 – 1.305)

0.804

1.012 (0.795 – 1.288)

0.924

0.949 (0.700 – 1.288)

0.738

Yes vs No (255/840)

Cardiac disease

1.162 (0.947 – 1.427)

0.150

1.016 (0.772 – 1.337)

0.909

1.162 (0.947 – 1.426)

0.151

1.019 (0.774 – 1.342)

0.895

Yes vs No (462/633)

Renal disease

2.583 (1.777 – 3.754)

<0.001*

3.139 (1.854 – 5.317)

<0.001*

2.588 (1.780 – 3.761)

<0.001*

3.101 (1.830 – 5.254)

<0.001*

Yes vs No (52/1043)

Chemotherapy

1.509 (1.188 – 1.916)

<0.001*

1.233 (0.831 – 1.828)

0.298

1.580 (1.188 – 1.915)

0.001*

1.230 (0.830 – 1.824)

0.302

Yes vs No (731/360)

  1. aAJCC American Joint Commission on Cancer, bPD Poorly differentiated, MD Moderately differentiated, WD Well differentiated
  2. cCEA Carcinoembryonic antigen, dHR Hazard ratio, eConfidence interval
  3. *Indicated P < 0.05